ebastine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics 977 90729-43-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ebastine
  • bastel
  • ebastel
  • ebastin
  • erostin
  • kestine
non-sedating second generation antihistamine which is used for allergic disorders
  • Molecular weight: 469.67
  • Formula: C32H39NO2
  • CLOGP: 6.94
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -6.86
  • ROTB: 10

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.61 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1990 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 108.19 22.09 78 3073 135807 53210108
Allergy test positive 75.61 22.09 14 3137 381 53345534
Gallbladder polyp 66.24 22.09 14 3137 759 53345156
Angioedema 52.40 22.09 32 3119 42044 53303871
Drug reaction with eosinophilia and systemic symptoms 43.55 22.09 26 3125 32774 53313141
Mixed liver injury 27.87 22.09 10 3141 3923 53341992
Mechanical urticaria 27.42 22.09 6 3145 383 53345532
Sprue-like enteropathy 26.00 22.09 6 3145 487 53345428
Oesophagitis 25.84 22.09 14 3137 14663 53331252
Pyrexia 24.35 22.09 65 3086 403128 52942787
Rhinorrhoea 23.88 22.09 22 3129 53556 53292359
Aspartate aminotransferase increased 23.77 22.09 27 3124 84002 53261913

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dental caries 79.28 25.71 23 1897 4621 32506985
Vitamin D deficiency 57.12 25.71 19 1901 5975 32505631
Diabetes mellitus inadequate control 54.82 25.71 23 1897 13745 32497861
Blood pressure fluctuation 49.44 25.71 24 1896 20111 32491495
Hepatitis 42.91 25.71 23 1897 23670 32487936
Musculoskeletal stiffness 34.53 25.71 24 1896 39240 32472366
Eczema 34.20 25.71 17 1903 14963 32496643
Colitis 32.81 25.71 22 1898 33929 32477677
Hypocoagulable state 31.28 25.71 8 1912 1000 32510606
Gastrointestinal disorder 29.78 25.71 20 1900 30911 32480695
Haematochezia 27.71 25.71 21 1899 39187 32472419
Rheumatoid arthritis 27.45 25.71 22 1898 44522 32467084

Pharmacologic Action:

SourceCodeDescription
ATC R06AX22 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Chronic idiopathic urticaria indication 302162004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.87 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8 WOMBAT-PK SCIENTIFIC LITERATURE
D(2) dopamine receptor GPCR IC50 7.21 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.51 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.55 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.82 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.19 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.34 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR IC50 7.33 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 7.59 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.70 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.91 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.99 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.47 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.38 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.54 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR IC50 5.96 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.55 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.86 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 6.22 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.62 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.72 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 7.11 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.74 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 6.34 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 6.06 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 5.13 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 6.25 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 6.09 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.98 DRUG MATRIX
Substance-K receptor GPCR Ki 6.19 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.94 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.63 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.85 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.87 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.58 CHEMBL
Histamine H1 receptor GPCR IC50 7.35 CHEMBL

External reference:

IDSource
D01478 KEGG_DRUG
C0058895 UMLSCUI
CHEBI:31528 CHEBI
CHEMBL305660 ChEMBL_ID
DB11742 DRUGBANK_ID
C058249 MESH_SUPPLEMENTAL_RECORD_UI
5633 INN_ID
TQD7Q784P1 UNII
3191 PUBCHEM_CID
23796 RXNORM
007136 NDDF

Pharmaceutical products:

None